References
- Smalley R V, Anderson J W, Hawkins M J. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336–1341
- Preisler H D, Gopal V. Regrowth resistance in leukemia and lymphoma: The need for a new system to classify treatment failure and for new approaches to treatment. Leukemia Research 1994; 18: 149–160
- McKelvey E M, Gottlieb J A, Wilson H E, et al. Hydroxydaunomycin (Adriamycin combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
- DeVita V T, Jr, Canellos G P, Chabner B A, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1975; 1: 248–250
- Schein P S, DeVita V T, Jr, Hubbard S, et al. Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Int Med 1976; 85: 417–422
- Gaynor E R, Ultmann J E, Golomb H M, et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (Cyclophosphamide, Oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol 1985; 3: 1596–1604
- Skarin A T, Canellos G P, Rosenthal D S, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–98
- Skarin A T, Canellos G P, Rosenthal D S, et al. Moderate dose methotrexate (M) combined with bleomycin (B), adriamycin (A), cyclophosphamide (C), Oncovin (O) and dexamethasone (D), M-BACOD in advanced diffuse histiocytic lymphoma (DHL). Pro Am Soc Clin Oncol 1983; 2: 20, abstr
- Klimo P, Connnors J M. Updated clinical experience with MACOP-B. Semin Hematol 1987; 2(Suppl 1)26–34
- Fisher R I, Young R C, Longo D, et al. PROMACE-MOPP combination chemotherapy for diffuse lymphomas. Semin Oncol 1985; 12: 29–32
- Fisher R I, DeVita V T, Hubbard S M, et al. Randomized trial of PROMACE-MOPP vs. CHOP in previously untreated, advanced stage diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 1984; 3: 242, abstr
- Longo D, DeVita V, Duffey D, et al. Randomized trial of PROMACE-MOPP (day 1(D)1, D8) (PM) vs. PROMACE-CytaBOM (PC) in stage II-IV aggressive non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1987; 6: 206, abstr
- Boyd D B, Coleman M, Papish S W, et al. COP-BLAM III: Infusional combination chemotherapy for diffuse large cell lymphoma. J Clin Oncol 1988; 46: 425–433
- Goldie J H, Coleman A J, Gudauska G A. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treatment Rep 1982; 66: 439–449
- Preisler H D, Venugopal P. Regrowth resistance in cancer: Why it has been largely ignored. Cell Prolif 1995; 28: 347–356
- Fisher R I, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
- Johnson G J, Costello W G, Oken M M. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPO's). Cancer 1983; 52: 1133–1141
- Carde P, Meerwaldt J H, van Glabbeke M, et al. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high grade non-Hodgkin's lymphoma. The 1980–85 EORTC Trial. Ann Oncol 1991; 2: 431–435
- Foon K A, Sherwin S A, Abrams P A, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte α-interferon. N Engl J Med 1984; 311: 1148–1152
- Aviles A, Diaz-Maqueo J C, Garcia E L, et al. Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Investigational New Drugs 1992; 10: 351–355
- Enschede S H, Shahidi H, et al. Lack of severe toxicity of interferon-alfa added to an anthracycline-based regimen in treating low grade and intermediate grade non-Hodgkin's lymphoma. B Cell Lymphoproliferative Disorders. New York, New York April 18–21, 1998, abstr 72